MAIA Biotechnology Awarded $2.3 Million Grant by National
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept.…
- Wed. Apr 15th, 2026
Where Innovation Meets Excellence